Faecal haemoglobin concentration thresholds for reassurance and urgent investigation for colorectal cancer based on a faecal immunochemical test in symptomatic patients in primary care.
Colorectal cancer
colorectal disease
faecal biomarkers
faecal haemoglobin
faecal immunochemical test
primary care
Journal
Annals of clinical biochemistry
ISSN: 1758-1001
Titre abrégé: Ann Clin Biochem
Pays: England
ID NLM: 0324055
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
pubmed:
19
12
2020
medline:
21
7
2021
entrez:
18
12
2020
Statut:
ppublish
Résumé
Faecal haemoglobin concentration (f-Hb), estimated using a faecal immunochemical test, can be safely implemented in primary care to assess risk of colorectal cancer (CRC). Clinical outcomes of patients presenting with symptoms of lower gastrointestinal disease were examined using an extensive range of f-Hb thresholds to decide on reassurance or referral for further investigation. All patients who attended primary care and submitted a single faecal specimen faecal immunochemical test in the first year of the routine service had f-Hb estimated using HM-JACKarc: f-Hb thresholds from <2 to ≥ 400 µg Hb/g faeces (µg/g) were examined. Low f-Hb thresholds of <2, <7, <10 and <20 µg/g gave respective CRC risks of 0.1, 0.3, 0.3 and 0.4%, numbers needed to scope for one CRC of 871, 335, 300 and 249, and 'false negative' rates of 2.9, 11.4, 13.3 and 17.1%. With thresholds of <2, <7, <10 and <20 µg/g, 48.6, 74.6, 78.1 and 83.2% respectively of symptomatic patients could be managed without further investigation. With reassurance thresholds of <2 µg/g, <7 µg/g and <10 µg/g, the thresholds for referral for urgent investigation would be >400 µg/g, ≥200 µg/g and ≥100 µg/g. However, patients with a f-Hb concentration of <10 or <20 µg/g with iron deficiency anaemia, or with severe or persistent symptoms, should not be denied further investigation. In primary care, f-Hb, in conjunction with clinical assessment, can safely and objectively determine individual risk of CRC and decide on simple reassurance or urgent, or routine referral.
Sections du résumé
BACKGROUND
Faecal haemoglobin concentration (f-Hb), estimated using a faecal immunochemical test, can be safely implemented in primary care to assess risk of colorectal cancer (CRC). Clinical outcomes of patients presenting with symptoms of lower gastrointestinal disease were examined using an extensive range of f-Hb thresholds to decide on reassurance or referral for further investigation.
METHODS
All patients who attended primary care and submitted a single faecal specimen faecal immunochemical test in the first year of the routine service had f-Hb estimated using HM-JACKarc: f-Hb thresholds from <2 to ≥ 400 µg Hb/g faeces (µg/g) were examined.
RESULTS
Low f-Hb thresholds of <2, <7, <10 and <20 µg/g gave respective CRC risks of 0.1, 0.3, 0.3 and 0.4%, numbers needed to scope for one CRC of 871, 335, 300 and 249, and 'false negative' rates of 2.9, 11.4, 13.3 and 17.1%. With thresholds of <2, <7, <10 and <20 µg/g, 48.6, 74.6, 78.1 and 83.2% respectively of symptomatic patients could be managed without further investigation. With reassurance thresholds of <2 µg/g, <7 µg/g and <10 µg/g, the thresholds for referral for urgent investigation would be >400 µg/g, ≥200 µg/g and ≥100 µg/g. However, patients with a f-Hb concentration of <10 or <20 µg/g with iron deficiency anaemia, or with severe or persistent symptoms, should not be denied further investigation.
CONCLUSIONS
In primary care, f-Hb, in conjunction with clinical assessment, can safely and objectively determine individual risk of CRC and decide on simple reassurance or urgent, or routine referral.
Identifiants
pubmed: 33334134
doi: 10.1177/0004563220985547
pmc: PMC8114428
doi:
Substances chimiques
Hemoglobins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
211-219Références
Colorectal Dis. 2018 Dec;20(12):O335-O342
pubmed: 30248228
Colorectal Dis. 2013 Mar;15(3):e151-9
pubmed: 23199241
Br J Gen Pract. 2020 Aug 27;70(698):e612-e621
pubmed: 32839162
N Engl J Med. 2006 Nov 2;355(18):1863-72
pubmed: 17079760
Colorectal Dis. 2020 Jun;22(6):679-688
pubmed: 31876975
BMJ Open Gastroenterol. 2019 May 4;6(1):e000293
pubmed: 31275586
Ann R Coll Surg Engl. 2020 Mar;102(3):174-179
pubmed: 31697171
J Clin Pathol. 2021 Mar;74(3):163-166
pubmed: 32646926
Br J Gen Pract. 2020 May 28;70(695):e389-e398
pubmed: 32312762
Clin Chem Lab Med. 2020 Jul 21;59(1):173-178
pubmed: 32692692
Colorectal Dis. 2013 Aug;15(8):963-7
pubmed: 23656572
Ann Clin Biochem. 2020 Jul;57(4):325-327
pubmed: 32482080
Aliment Pharmacol Ther. 2020 Sep;52(6):1031-1041
pubmed: 32677733
United European Gastroenterol J. 2021 Mar;9(2):256-267
pubmed: 32778002
BMJ. 2019 Nov 13;367:l6090
pubmed: 31722875
Gastroenterol Hepatol. 2019 Apr;42(4):263-270
pubmed: 30459060
Br J Surg. 2020 Jun;107(7):e204
pubmed: 32400893
Gut. 2016 Sep;65(9):1463-9
pubmed: 26294695
Br J Hosp Med (Lond). 2019 Jan 2;80(1):22-26
pubmed: 30592674
Aliment Pharmacol Ther. 2017 Jan;45(2):354-363
pubmed: 27910113
Clin Chem Lab Med. 2019 Apr 24;57(5):611-616
pubmed: 29995629
Dig Liver Dis. 2015 Sep;47(9):797-804
pubmed: 26055489
BJS Open. 2020 Sep 18;:
pubmed: 32949085
World J Gastrointest Oncol. 2015 Dec 15;7(12):422-33
pubmed: 26690833
Gut. 2021 Jun;70(6):1130-1138
pubmed: 33087488
Colorectal Dis. 2020 Oct 16;:
pubmed: 33064898
Clin Chem Lab Med. 2016 Apr;54(4):595-602
pubmed: 26457785
Gut. 2017 Sep;66(9):1631-1644
pubmed: 27267903
Surgeon. 2021 Apr;19(2):93-102
pubmed: 32327303